Anti-(+)-Methamphetamine Monoclonal Antibody Antagonists Designed to Prevent the Progression of Human Diseases of Addiction

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 3, 2010, Pages 390-393

  Gentry, W B ^a   Ruedi Bettschen D ^a   Owens, S M ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G2B; METHAMPHETAMINE; MONOCLONAL ANTIBODY; PENTOBARBITAL;

BLOOD BRAIN BARRIER; COCAINE DEPENDENCE; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEROIN DEPENDENCE; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; SHORT SURVEY;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; ANTIBODIES, MONOCLONAL; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; METHAMPHETAMINE; RECURRENCE;

EID: 77955923552     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.155     Document Type: Short Survey

References (21)

1. Byrnes-Blake, K.A., Laurenzana, E.M., Landes, R.D., Gentry, W.B. & Owens, S.M. Monoclonal IgG afnity and treatment time alters antagonism of (+)-methamphetamine efects in rats. Eur. J. Pharmacol. 521, 86-94 (2005).
2. Laurenzana, E.M., Byrnes-Blake, K.A., Milesi-Hallé, A., Gentry, W.B., Williams, D.K. & Owens, S.M. Use of anti-(+)-methamphetamine monoclonal antibody to signifcantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab. Dispos. 31, 1320-1326 (2003).
3. Laurenzana, E.M. et al. Functional and biological determinants afecting the duration of action and efcacy of anti-(+)-methamphetamine monoclonal antibodies in rats. Vaccine 27, 7011-7020 (2009).
4. Lacy, H.M., Gunnell, M.G., Laurenzana, E.M. & Owens, S.M. Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody. Int. Immunopharmacol. 8, 1-11 (2008).
5. Martell, B.A. et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efcacy trial. Arch. Gen. Psychiatry 66, 1116-1123 (2009).
6. Hatsukami, D.K. et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther. 78, 456-467 (2005).
7. Tabrizi, M.A. & Roskos, L.K. preclinical and clinical safety of monoclonal antibodies. Drug Discov. Today 12, 540-547 (2007).
8. Cook, C.E. et al. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking s-(+)-methamphetamine hydrochloride. Drug Metab. Dispos. 21, 717-723 (1993).
9. Oldendorf, W.H. some relationships between addiction and drug delivery to the brain. NIDA Res. Monogr. 120, 13-25 (1992).
10. Cho, A.K. Ice: a new dosage form of an old drug. Science 249, 631-634 (1990).
11. Fischman, M. & Schuster, C. Cocaine self-administration in humans. Fed. Proc. 41, 241-246, (1982).
12. Balster, R.L. & Schuster, C.R. Fixed-interval schedule of cocaine reinforcement: efect of dose and infusion duration. J. Exp. Anal. Behav. 20, 119-129 (1973).
13. De Wit, H., Bodker, B. & Ambre, J. Rate of increase of plasma drug level infuences subjective response in humans. Psychopharmacology (Berl.) 107, 352-358 (1992).
14. Roopenian, D.C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715-725 (2007).
15. Pentel, P.R., Dufek, M.B., Roiko, S.A., Lesage, M.G. & Keyler, D.E. Diferential efects of passive immunization with nicotine-specifc antibodies on the acute and chronic distribution of nicotine to brain in rats. J. Pharmacol. Exp. Ther. 317, 660-666 (2006).
16. Carroll, F.I. et al. The synthesis of haptens and their use for the development of monoclonal antibodies for treating methamphetamine abuse. J. Med. Chem. 52, 7301-7309 (2009).
17. Pitas, G., Laurenzana, E.M., Williams, D.K., Owens, S.M. & Gentry, W.B. Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of efectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab. Dispos. 34, 906-912 (2006).
18. Tuncok, Y. et al. Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion. Exp. Clin. Psychopharmacol. 9, 228-234 (2001).
19. Laurenzana, E.M., Gunnell, M.G., Gentry, W.B. & Owens, S.M. treatment of adverse efects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. J. Pharmacol. Exp. Ther. 306, 1092-1098 (2003).
20. Roiko, S.A., Harris, A.C., Keyler, D.E., Lesage, M.G., Zhang, Y. & Pentel, P.R. Combined active and passive immunization enhances the efcacy of immunotherapy against nicotine in rats. J. Pharmacol. Exp. Ther. 325, 985-993 (2008).
21. Joos, B. et al. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodefciency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob. Agents Chemother. 50, 1773-1779 (2006).